Xiangshaliujunzi Decoction for the treatment of diabetic gastroparesis: A systematic review

Table 1 Characteristics of included randomized controlled trials

Trials	Sample size	Gender (E/C)	Experimental group	Control group	Period	Outcome measure	Balance report of baseline
Cai[31]	54 (27/27)	(15M:12F)/(14M:13F)	Modified Xiangshaliujunzi Decoction, bid	Metoclopramide (10 mg, tid)	4 W	Clinical effective rateGastric emptying testGI symptomsAdverse events	P > 0.05
Feng[32]	128 (64/64)	(30M:34F)/(34M:30F)	Modified Xiangshaliujunzi Decoction, bid	Cisapride (10 mg, tid), Metoclopramide (10 mg, bid)	4 W	Clinical effective rateGI symptoms	P > 0.05
Guo et al[33]	62 (32/30)	(35M:27F)	Modified Xiangshaliujunzi Decoction, bid	Domperidone (10 mg, tid)	8 W	Clinical effective rateGI symptoms	P > 0.05
Lu[34]	94 (48/46)	(28M:20F)/(24M:22F)	Modified Xiangshaliujunzi Decoction, bid	Domperidone (10 mg, tid)	4 W	Clinical effective rateGI symptoms	P > 0.05
Lu et al[35]	142 (72/70)	(30M:42F)/(31M:39F)	Modified Xiangshaliujunzi Decoction, bid	Mosapride (5 mg, tid)	4 W	Clinical effective rateGastric emptying testGI symptoms	P > 0.05
Meng[36]	62 (32/30)	(15M:17F)/(14M:16F)	Modified Xiangshaliujunzi Decoction, bid	Cisapride (10 mg, tid), Metoclopramide (10 mg, bid)	4 W	Clinical effective rateGI symptoms	P > 0.05
Wen[37]	87 (44/43)	(25M:19F)/(23M:20F)	Modified Xiangshaliujunzi Decoction, bid	Cisapride (5 mg, tid)	4 W	Clinical effective rateGastric emptying testGI symptomsAdverse events	No significant differences
Dai[38]	70 (36/34)	(22M:14F)/(20M:14F)	Modified Xiangshaliujunzi Decoction, bid	Domperidone (10 mg, tid)	3 W	Clinical effective rate Gastric emptying testGI symptoms	P > 0.05
Ji[39]	56 (30/26)	(14M:16F)/(12M:14F)	Modified Xiangshaliujunzi Decoction, bid	Domperidone (10 mg, tid)	2 W	Clinical effective rateGI symptoms	No significant differences
Hou et al[40]	112 (56/56)	(44M:12F)/(43M:13F)	Modified Xiangshaliujunzi Decoction, bid	Domperidone (10 mg, tid)	8 W	Clinical effective rateGastric emptying testGI symptoms	P > 0.05

GI: Gastrointestinal; M: Male; F: Female.

Table 2 Quality assessment of included randomized controlled trials

Trials	Randomization	Allocation concealment	Blinding of participants and personnel	Blinding of assessors	Incomplete outcome data	Selective reporting	Other sources of bias	Risk of bias
Cai[31]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Feng[32]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Guo et al[33]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Lu[34]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Lu et al[35]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Meng[36]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Wen[37]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Dai[38]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Ji[39]	Unclear	Unclear	High	Unclear	Yes	No	Unclear	High
Hou et al[40]	Table of random number	Unclear	High	Unclear	Yes	No	Unclear	Unclear